Amgen has communicated with regulatory authorities and is in the process of
notifying study investigators that treatment with ganitumab should be discontinued in the GAMMA trial, as well as a separate ongoing Phase 2 trial in locally advanced pancreatic cancer.
Notify the study investigator or your veterinarian regarding any changes in the health of your animal or your willingness to participate in the study.
Not exact matches
The
investigators would have been
notified of the results prior to completion of the
study only if a difference in pregnancy rates or STI rates with a critical P value of less than or equal to.001 was observed between either the pharmacy access group or the advance provision group compared with the clinic access group.